Federal grant · project grant (b)
Developing an Anti-proteotoxicity Therapy for Neurodegenerative Diseases - Project Summary Protein Quality Control Is a Fundamental System in the Cell That Is Important for Normal Cellular Functions and Defense Against Potential Pathogenic Insults. Protein Misfolding and Aggregation Are a Central Feature of Many Neurodegenerative Diseases Including Alzheimer’s Disease (ad), Frontotemporal Dementia (FTD), and Amyotrophic Lateral Sclerosis (als). the Complexity of Neurodegeneration Calls for Large-scale Unbiased Screening Studies. Over the Past Few Years, We Have Made Breakthrough Observations That Have Significant Implications for the Understanding of Cellular Defense Systems Against Proteotoxicity. Using a Unique Blend of Biochemical, Genetic, and Cell Biological Approaches, We Discovered a Novel Pathway to Reprogram Protein Quality Control, and With New Genetic Hits Related to This Pathway. Our Work Has Elucidated a Previously Unrecognized Network in Protein Quality Control. the Studies on This Network Could Expand Our Understanding of Proteotoxic-stress-responsive Quality Control Systems in the Cell, Beyond the Well-established Heat Shock Response or Unfolded Protein Response. the Findings Will Suggest New Strategies for Harnessing the Cellular Defense System to Prevent and Treat the Relevant Forms of Neurodegenerative Diseases Associated With Proteotoxicity. Our Project Will Be Focused on Investigating Novel Molecular Targets That Are Identified Through Unbiased Screens and Testing New Small Molecule Compounds That Have Been Designed to Be Specific Inhibitors of This Target. We Predict That the Advances Gained Through Our Research Efforts Will Eventually Lead to New Therapeutic Interventions to Address the Relevant Neurodegenerative Diseases.
Committed
$694,318
Paid out
$475.0K
68%
Committed, not yet paid
$219.3K
32%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…